Cart
sales@molnova.com
Flavopiridol hydrochloride
CAS No. 131740-09-5
Flavopiridol hydrochloride( HL 275 | NSC 649890 | MDL 107826A | | Alvocidib Hydrochloride )
Catalog No. M11289 CAS No. 131740-09-5
A potent, ATP-competetive CDKs inhibitor with IC50 of 30, 170, 100 nM for CDk1, 2, 4, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 46 | In Stock |
|
| 5MG | 42 | In Stock |
|
| 10MG | 67 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFlavopiridol hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, ATP-competetive CDKs inhibitor with IC50 of 30, 170, 100 nM for CDk1, 2, 4, respectively.
-
DescriptionA potent, ATP-competetive CDKs inhibitor with IC50 of 30, 170, 100 nM for CDk1, 2, 4, respectively; inhibits cell cycle progression in either G1 or G2 in human breast carcinoma cells, induces programmed cell death, promote differentiation, inhibits angiogenic processes and modulates transcriptional events.Blood Cancer Phase 2 Clinical(In Vitro):Flavopiridol (2 μM) robustly induces a distinct pattern of ER stress in CLL cells that contributes to cell death through IRE1-mediated activation of ASK1 and possibly downstream caspases. Flavopiridol results in potent upregulation of a number of PRGs in treatments lasting 4-24 h. Flavopiridol has and immediate and long-term effect on the expression of several PRGs. In serum starved cells re-stimulated with serum, flavopiridol also inhibits the expression of these genes, but subsequently, JUNB, GADD45B and EGR1 are upregulated in the presence of flavopiridol.
-
In VitroFlavopiridol (2 μM) robustly induces a distinct pattern of ER stress in CLL cells that contributes to cell death through IRE1-mediated activation of ASK1 and possibly downstream caspases. Flavopiridol results in potent upregulation of a number of PRGs in treatments lasting 4-24 h. Flavopiridol has and immediate and long-term effect on the expression of several PRGs. In serum starved cells re-stimulated with serum, flavopiridol also inhibits the expression of these genes, but subsequently, JUNB, GADD45B and EGR1 are upregulated in the presence of flavopiridol.
-
In Vivo——
-
SynonymsHL 275 | NSC 649890 | MDL 107826A | | Alvocidib Hydrochloride
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK1|CDK2|CDK4|CDK6|CDK7
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number131740-09-5
-
Formula Weight438.3011
-
Molecular FormulaC21H21Cl2NO5
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl
-
Chemical Name4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-, hydrochloride (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. De Azevedo WF Jr, et al. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2735-40.
2. Carlson BA, et al. Cancer Res. 1996 Jul 1;56(13):2973-8.
3. Senderowicz AM, et al. Invest New Drugs. 1999;17(3):313-20.
4. Kim KS, et al. J Med Chem. 2000 Nov 2;43(22):4126-34.
molnova catalog
related products
-
Senexin C
Senexin C is a novel orally active and specific CDK8/19 inhibitor with potential anticancer activity.Senexin C is more metabolically stable and potent than Senexin B. Senexin C inhibits the growth of MV4-11 leukaemia cells.
-
BAY 1251152
BAY 1251152 is the first potent, selective, orally available PTEFb/CDK9 inhibitor with biochemical IC50 of 9 nM and MOLM13 cell IC50 of 29 nM.
-
Riviciclib
A novel potent CDK inhibitor with IC50 of 79 nM, 63 nM and 20 nM for Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, respectively.
